Search Results
Randomized Placebo-controlled Trial of Nicotine Pouches in Smokers
The purpose of this research study is to understand the health effects of a new oral nicotine pouch, and also to understand if this product can help reduce traditional cigarette smoking. Participants will be asked to reduce their cigarette smoking by at least 50% with the help of the nicotine pouches.
After smoking your usual brand cigarettes for one week, you will be randomly assigned to one of six nicotine pouch groups to use over 16 weeks and asked to reduce your cigarette smoking over that time by at least 50% by using a nicotine pouch in place of your cigarettes. During the 16 weeks, there will be 2 phone call contacts and 4 in-person study contacts. During in-person contacts you will complete study questionnaires and you will be asked to provide urine, exhaled carbon monoxide, mouth cell samples, and other health measurements. You will record your cigarette and nicotine pouch use every day through a daily text message. Lastly, you will be followed up for a last study contact (virtual) 4 weeks later.
$500
Commonly smoke ≥ 5 cigarettes or little cigars/small cigars/cigarillos/filtered cigars per day (at least 2 days/week) for at least the prior 12 months
Smoke cigarettes daily
Must be interested in reducing cigarette consumption by at least 50% and willing to try nicotine pouches
Access to e-mail and a smartphone/computer that has reliable internet connection
Use of a nicotine pouch or other non-cigarette nicotine product (e-cigarette, pipe, cigar, chew, snus, hookah, IQOS) for 10 or more days in the past 28 days
Currently pregnant, breastfeeding, or planning to become pregnant
Use of any FDA-approved smoking cessation medication (including any nicotine replacement therapy or varenicline, bupropion or nortriptyline used specifically as a smoking cessation aid) in the prior month
Use of illegal drugs weekly or more in the past 3 months
Childhood Adverse Experiences: Impacts in Young Adulthood
The purpose of the study is to examine how individuals change over time and what impacts their development. In particular, we are interested in mental health outcomes in young adulthood. Participants will be required to complete a survey one time that will take about 10-15 minutes to complete. Participants will be eligible to win a $10.00 amazon gift card.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety andEfficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis
A Phase 2 Clinical Trial to assess whether study drug DWN12088 is safe and effective in Patients With Idiopathic Pulmonary Fibrosis
During this study, you will be asked to come to in-person visits at the Hershey Medical Center over a period of 6 months During that time you will visit the study center 8 times and have various tests done including: signing informed consent, providing demographics, having a chest CT scan, reviewing medical history, having a physical exam done, having vital signs and an ECG taken, having bloodwork done, receiving study drug, receiving patient diaries, having study drug administered, performing lung function tests (spirometry, DLCO and 6-minute walk test), and completing questionnaires.
Diagnosed with idiopathic pulmonary fibrosis in the past 5 years
Able to walk 150 meters (492 feet) in 6 minutes
Lower respiratory tract infections requiring antibiotics in the last 4 weeks
Female participants who are pregnant or nursing
Use of investigational drugs for idiopathic pulmonary fibrosis in the last 4 weeks
A Phase II Pilot Trial to Estimate Survival After a Non-Total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed with B-Acute Lymphoblastic Leukemia (ALL) Who Are Pre-Allogeneic Hematopoietic Cell Transplantation (HCT) Next-Generation-Sequence (NGS) Minimal Residual Disease (MRD) Negative
A study of the safety and efficacy of removing the total body irradiation part of the treatment of pediatric patients with B-ALL who are negative before their transplant to a sensitive sequencing test which measures minimal residual disease.
•Bone marrow and blood tests: for about a year extra bone marrow and blood will be collected for the disease NGS-MRD (next-generation-sequence minimal residual disease) testing to detect if you have any leukemia.•Let the research team record information from your medical record related to your condition and the treatment you receive.•If your NGS-MRD testing before your transplant shows that you are eligible for the Non-TBI (Total Body Irradiation) Arm of the study, it will be explained to you in a different consent form.
Diagnosis of High Risk B-ALL (Acute Lymphoblastic Leukemia) in CR1 (complete remission) after first-line treatment
Philadelphia chromosome positive (Ph+) ALL (Acute Lymphoblastic Leukemia)
Prior tyrosine kinase inhibitor therapy
Mechanisms of New-Onset Autoimmunity-Longitudinal Immune Systems Analysis
The purpose of this study is to investigate why some individuals who have a few findings of autoimmunity eventually develop a condition such as systemic lupus erythematosus (SLE). In addition to stored biosamples from the SMILE clinical trial, new samples will be collected from persons with findings such as lab tests that are suggestive of lupus with an emphasis on recruitment of individuals ofnon-European ancestry, who were under-represented in the previous clinical trial.
Participants in this study will answer questions about their health and have a short physical exam performed on them. They will provide a blood and urine sample. These procedures will be repeated every twelve months for three years (a total of four times). Both routine and experimental tests will be performed on the blood and urine samples. Genetic studies will be done to help understand the risk of developing lupus.
positive ANA test of at least 1:80
Have one or more additional features of lupus
Able to give assent or consent.
Current or past use of immunosuppressants
Have a diagnosis of another autoimmune disease, other than autoimmune thyroid disease.
Human-AI Interaction
We are conducting a series of focus groups to examine why people use technologies driven by artificial intelligence, and what gratifications people gain from those interactions. This is part of a larger project to understand human-AI interaction (HAII), a relatively new concept in the field of human-computer interaction. Our goal is to help pioneer a definition of HAII by first understanding the basics of how and why people use AI-driven technologies. Focus groups will consist of 5-10 people and will take no more than one hour to complete. All consenting adults near the State College area are welcome to participate.
Able to participate in-person in State College
Willing to discuss technology habits in a group setting
Unable to attend in-person focus groups
Atrophy of Olfactory Bulb in Early-stage Parkinson’s disease
This research is being done to study the deterioration of the central olfactory system (sense of smell system) in the brains of patients diagnosed with early- stage Parkinson’s disease.
Patients should not have reached their 65th birthday.
Patients that have tremor, rigidity, and bradykinesia unilaterally
Autonomic dysfunction
Parkinson-plus syndrome
Postural instability
History of exposure to substances that cause parkinsonism
PSCI 22-120 A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of AAV2-hAQP1 Gene Therapy in Participants with Radiation-Induced Late Xerostomia
This trial will be comparing two doses of AAV2-hAQP1 against a placebo for patients with head and neck cancer who have severe dry mouth from receiving radiation.
Patient's will be required to come to all study visits, reports any signs and symptoms they are having and all medications they are taking. You will be required to come in for 2 pre screening visits that will include signing the consent, collecting of saliva, completing questionnaires, seeing the study doctor, having blood drawn, providing a urine specimen to see if you qualify to participate. If you meet the qualifications to participate you will have one visit in which you will receive medication to dry your mouth, than the study doctor will place the medication into the glands in your mouth that produce saliva. You will then be requires to come in the next week for additional saliva collection and to see the study doctor. After that you will come in monthly to see the study doctor too see how you are feeling,complete questionnaires and provide a urine specimen.
dependent upon miles traveled
Age ≥18 years
Able to understand the investigational nature, potential risks, and benefits of the study, and to provide valid informed consent to enroll in this study and in the long-term follow-up study
Completed beam radiation therapy for head and neck cancer at least 3 years prior to the first screening visit
No history of recurrent cancer or a second primary cancer
Any experimental therapy within 3 months prior to the first screening visit
Previous treatment with a gene or cell therapy
History of systemic autoimmune disease affecting the salivary glands (e.g., Sjogren’s disease)
Currently using systemic immunosuppressive medication(s)
One Penn State : Connecting a Learning Community of Geographically Diverse Students
The community of remote learners is on the rise. With the trends of application and skill based knowledge, more and more people are migrating to the learn while you work paradigm. People value flexibility and comfort increasingly. Penn State is one of the few Universities propagating the cause of spreading knowledge via all modalities. The 33,302 students spread across its 19 commonwealth campuses are further a testimony to the prevalent trends. It is important that all these students receive an integrated and cohesive student experience. This also covers the need for the students to feel a sense of social belongingness. The work will focus on bringing together the Penn State community to achieve the true essence of it’s chant WeAre!
Must be a student of Penn State
The Role of Parental Emotion Regulation in Parent-Child Conflicts
This study seeks to examine parenting skills in responses to child misbehavior. Parents complete rating scales about their child's symptoms and behaviors and also participate in computer tasks to measure brain wave activity through EEG. There is an optional section where parent and child will be video recorded while completing activities together. Following the testing sessions are 8 weeks of counseling sessions for parents to help better manage their child's attention and behavior symptoms.
Participants will complete C-DISC while caregiver will complete rating scales around ADHD, ODD, and CD symptoms during initial visit. On the second visit, participants will complete emotion regulation tasks while EEG data is collected. Caregivers will also complete a monetary task while connected to EEG equipment. Parents will use LifeData to report inattentiveness, hyperactivity, and oppositional behaviors over 14 days. Optional parent child interaction and 8-week parenting intervention are offered to participating families.
$50
Child must have mild to moderate symptoms of ODD
Non-English speaking
Child with ADHD has diagnosis of mental retardation or prominent traits of autism
No additional child in the family can be enrolled simultaneously in this study
NASH AMPK Exercise Dosing (AMPED) Trial
The purpose of this trial is to test different levels of exercise needed to reduce liver fat in patients with NASH.
If you take part in this research, your major responsibilities will include: •Completing exercise sessions (if randomized to exercise group). A typical exercise session will include a 5 minutes warm-up with stretching, 15-45 minutes of brisk walking, jogging or recumbent bike and a 5-minute cool-down.
250.00
NASH diagnosis
BMI 25-45 kg/m2
sedentary lifestyle
Active cardiac symptoms
Cancer that is active
Inability to provide informed consent
Other liver disease
Interoception, the 8th Sensory System, Is it measurable?
Sensory processing is often affected in children and adolescents with ASD (autism). The 8th sensory system, coined interoception, is under studied in how it affects children with autism. Our study will compare children with and without autism (ages 11-18 years) using a tool we are developing. Our study hopes to develop psychometric properties of a tool to measure this new sensory sense.
Reading at 5th grade level in English
Healthy controls OR high functioning Autism
Under age 11 or over age 18
Cannot read English
Social Media Usage Effect on Symptomatology for Those with Obsessive-Compulsive
This study seeks to explore how social media use may result in increased severity of compulsions and/or obsessions in those with symptoms of obsessive-compulsive disorder (OCD) during the COVID-19 pandemic. Participants will complete questionnaires, digital sleep and social media journals.
Part I: They will take surveys about sleep, social media use, and stress to establish the baseline, being asking to reduce social media use (experimental group) or not (control group) and then take the same surveys again.Part II: They will use an Oura ring to track their sleep for 14 days, and then take the surveys again.
$10 (Drawing for part I); part II $15
social media user
Individuals who display symptoms of obsessive-compulsive disorder (self-reported)
Has unlimited access to device for social media
Non-English speakers
Communicating Queer Chinese Identities: A Qualitative Investigation of the Visibility and Intelligibility of Transnational Queer Women in the United States
In today’s climate of anti-Asian hate, we believe that it is important to uncover different aspects of what “being Chinese” could look like. To this end, we are looking for individuals who self-identify as ethnically Chinese, woman, and a member of the LGBTQIA+ community to participate in a one-time 90-minute online interview to learn about what they do in their regular, everyday life to try to show or tell others about who they are. As part of the study, we will ask interviewees to share some visual images (e.g., photos, drawings, etc.) that they own as a way of elaborating on the ways that they communicate their self-identity in everyday life.
Chinese ethnicity
Woman
Non-woman
Not Chinese ethnicity
Translational Study on Temperature and Solvent Effects on Electronic Cigarette-Derived Oxidants
Determine if free radicals produced by electronic cigarettes or conventional cigarettes impact inflammation and oxidative stress responses in users.
Subjects will come to the Clinical Research Center at Hershey and if they are a nicotine user they will bring their device (cigarette or e-cigarette) with them. Healthy volunteers will answer the same questionnaires and provide the same samples but will not use any nicotine during their visit. They will provide blood, urine, buccal cell and exhaled breath condensate samples. They will be videotaped using their own devices and they will answer questionnaires. This is a one-time visit that will last around 2 hours.
100
For cigarette or e-cigarette users: No plan on quitting in the next 3 months
For e-cigarette users: E-cigarette use for more than 6 months
For cigarette users: Cigarette use for more than 6 months
For
Uncontrolled substance abuse
Pregnant or nursing
A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety ofSPN-812 in Preschool-Age Children (4 to 5 years old) with Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to learn more about the use of an investigational drug for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in preschool-aged (4-5 years old) children.
If after Visit 1 (Screening) your child is found to be eligible to take the study drug, he/she will need to come to the study center for 7 additional visits (Visits# 2-8; 6 weeks) and you will receive a follow-up phone call one week after your child’s last study visit (or after your child takes the last capsule of study drug). Most visits will be scheduled 1 week apart. Every participant will take 1 capsule each day for 6 weeks. Your child will either take one SPN-812 capsule every day for 6 weeks or a Placebo capsule every day for 6 weeks.
$650
Subject’s parent(s) or legal guardian(s)/representative(s) is (are) willing and able to provide written informed consent, including a signed Informed Consent Form
Has a primary diagnosis of ADHD
Is participating in a structured group activity (e.g., preschool, kindergarten, sports, Sunday school or child care program)
Is not currently receiving a behavioral intervention for ADHD at the time of screening nor plans to receiving a behavioral intervention for ADHD throughout their study
Has a current diagnosis of a major neurological disorder.
History of Bipolar Disorder diagnosed in a first degree relative.
Has global development delay or intellectual disability by medical history.
Has body mass index > 95th percentile for the subject’s age and gender.
The role of ocular and limb motor inhibition for dexterous motor control
In this project, participants will perform experiments where they will be asked to look at salient virtual targets and make reaching movements to those targets, while ignoring other visual stimuli presented to them.
During this study, we will ask you to come to our laboratory located in 23 Recreation Building, Penn State University, on a single day.We will ask you to perform an eye-hand coordination task using a robot. You will sit in a modified chair and grasp a handle that permits you to move your hand leftward, rightward, towards and away from your body. A display system will project visual targets into the same plane as your hands, which will allow you to interact virtually with the visual targets. These targets will be either bright or dark and you will be instructed to look at some of these targets (while ignoring others) and make reaching movements to some of these targets.
20
Male and female participants who volunteer for the study and provide informed consent.
Participants will be right-hand dominant individuals.
They will have normal or corrected-to-normal vision.
Participants should be able to sit upright in a chair for long periods (up to 2 and a half hours) with rest.
Any history of musculoskeletal disorders
Eye or vision problem
Cognitive impairment such that informed consent cannot be obtained, or that participant would not be safe with the protocol.
Medication that could make the participant drowsy or tired during the experiment
The Biomechanics of Golf Performance
The purpose of this study is to determine what golf equipment and swing characteristics best predict playing ability in a population of golfers. Golfers will hit shots with various clubs while the movement of their body, the club, and the ball are tracked.
Participants will come to the Penn State Golf Teaching and Research Center or the Penn State Golf Courses and hit golf shots using their driver, 7 iron, and putter. A golf monitor will be used to track the ball trajectory. The movements of participant's body, club, and ball will be measured in three-dimensions as they swing. Participants will receive brief feedback from a Class-A PGA Professional upon completion.
Participants will receive brief feedback from a Class-A PGA Professional upon completion.
Between ages of 18-75
Physically able to play a full round of golf (i.e., 18 holes)
Not between ages of 18-75
Not physically able to play a full round of golf (i.e., 18 holes)
The YA CS FEAST (Young Adult Cancer Survivors Food, Education, and Applied Skills to Thrive) Study
The purpose of this study is to test the acceptability and feasibility of an online cooking and nutrition intervention in young adult survivors of childhood cancer. During this single arm trial, participants will receive nutrition education based on the DASH diet and they will learn basic cooking skills to prepare healthy meals.
•Answer questionnaires•Provide urine samples•Attend 6 virtual group cooking lessons•Participate in an individual interview to provide feedback on the course
$210
Diagnosed with cancer before the age of 18
Completed treatment and has been in remission for at least 1 year
The Penn State Personalized Research for Innovation, Discovery, and Education (PRIDE) Program.
The Penn State Personalized Research for Innovation, Discovery, and Education (PRIDE) Program.The aims of the PRIDE Program are to:1. Create a centralized Biorepository using extra blood obtained from a clinically-ordered, or another IRB approved research protocol initiated blood draw, leftover biospecimens that are removed during medically indicated procedures or a saliva sample from consented participants that do not have clinically ordered blood draws or a medical procedure.2. Construct a dynamic database of health and related data (via both manual and electronic abstraction) from consented participants.3. Establish a mechanism for approving use of the banked biospecimens for future research.
The participant will meet with PRIDE Program team member in person to join the study.The participant with supply a saliva sample for the program.There is no compensation for joining the PRIDE Program.
Ability of patient, child and/or parent to understand or complete the consent process
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features
Radiation treatment and hormonal therapy vs. Radiation treatment, hormonal therapy plus Enzalutamide in post-prostatectomy cancer recurrences.
Radiation treatment and hormonal therapy vs. Radiation treatment, hormonal therapy plus Enzalutamide in post-prostatectomy cancer recurrences
PSA level (≥0.2 ng/mL) within 90 days prior to registration.
Hemoglobin ≥9.0 g/dL, independent of transfusion and/or growth factors within 90 days prior to registration.
At least 1 of the following features: • Gleason score of 8-10 • Seminal vesicle invasion • Locoregional node involvement at radical prostatectomy • Persistently elevated PSA post-RP nadir
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
A082002 Randomized Phase II/III of immunotherapy with or without SBRT PD-L1 negative NSCLC (22-026)
To assess if SBRT improves the progression free survival (PFS, phase II portion) and overall survival (OS, phase III portion) of advanced stage NSCLC patients with PD-L1 TPS <1% who receive immunotherapy with or without chemotherapy
We are asking you to take part in a research study. This study has public funding from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) in the United States Department of Health and Human Services. We do research studies to try to answer questions about how to prevent, diagnose, and treat diseases like cancer.
No prior systemic chemotherapy or immunotherapy for advanced NSCLC
Not pregnant and not nursing
No known history of Hepatitis B or Hepatitis C
Platelet Count ≥ 100,000/mm3
Current pneumonitis or history of non-infectious pneumonitis that required steroids
Prior allogeneic tissue/solid organ transplant.
Age < 18 years
ECOG Performance Status over 3
Livestreaming, Content Creation, and Playing and Learning Online
This study surveys how different viewers, livestreamers and content creators learn and engage online. We are recruiting people who view or create content on livestreaming platforms such as Twitch, YouTube or Mixer (past or present). This study involves filling out a survey which should take 15-20 minutes to complete. Participants will be entered into a drawing to win one of 20 $75 e-gift cards for their participation.
people who watch livestreams
aged 13 or older (if not yet legally adults, with parental/guardian permission)
online content creators
gamers or esports viewers
cannot read, communicate or provide consent in English
does not livestream or watch livestreams or create content online
if a minor, does not have parental/legal guardian permission
Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) (PSCI# 21-207) (NRG-HN009)
The purpose of this study is to compare two usual treatment approaches to your head and neck cancer: high-dose cisplatin given every 3 weeks with radiation to low-dose cisplatin given weekly with radiation. The first part of this study will help the study doctors find out if the low-dose cisplatin approach is better tolerated than the high-dose cisplatin approach. To decide if it is better, the study doctors will be looking to see if there are fewer side effects for patients who receive low-dose cisplatin weekly compared to patients who receive high-dose cisplatin every 3 weeks. The second part of this study will also help the study doctors find out if the low-dose cisplatin approach will extend your life by at least the same amount of time as the high-dose cisplatin approach. There will be 464 people in the first part of the study. If the study goes on to the second part, there will be 786 additional people. Overall, there will be a total of up to 1250 people taking part in this study.
he first part of this study will help the study doctors find out if the low-dose cisplatin approach is better tolerated than the high-dose cisplatin approach. To decide if it is better, the study doctors will be looking to see if there are fewer side effects for patients who receive low-dose cisplatin weekly compared to patients who receive high-dose cisplatin every 3 weeks.The second part of this study will also help the study doctors find out if the low-dose cisplatin approach will extend your life by at least the same amount of time as the high-dose cisplatin approach.There will be 464 people in the first part of the study. If the study goes on to the second part, there will be 786 additional people. Overall, there will be a total of up to 1250 people taking part in this study.
Age ≥ 18
Zubrod (ECOG) performance status of 0-1 within 14 days prior to registration
Adequate hematologic function within 30 days prior to registration
Adequate renal function within 30 days prior to registration defined as calculated creatinine clearance (CrCl) ≥ 50 mL/min by the Cockcroft-Gault formula
Definitive clinical or radiologic evidence of distant metastatic disease
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable, however, any prior exposure to cisplatin is excluded
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Pregnancy and individuals unwilling to discontinue nursing
Future of Construction Workplace Health Monitoring
This study will examine different structural designs of stretchable, skin-like sensors on the surface of human skin for construction workplace health monitoring.
There will be one in person visit, you will be asked to sit still for 3 minutes and then move your skin for another 3 minutes.
be over 18 years old.
must understand English.
from Penn State, University Park
cannot understand English
under 18 years old
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)
This is a drug study that will examine if inhaled treprostinil is save and effective in people diagnosed with Progressive Pulmonary Fibrosis.
You will be required to attend 8 in-person visits at the Hershey Medical Center over the span of approximately one year. During the study you will have physical examinations, complete questionnaires, review your medical history and current medications, have vital signs and ECGs taken, have blood tests performed, complete pulmonary function testing, and potentially have a high resolution CT scan done. You will take the inhaled treprostinil or placebo daily at home throughout the study.
600
Evidence of progression of pulmonary fibrosis in the last 24 months
Evidence of obstructive pulmonary disease
Concomitant use of both nintedanib and pirfenidone is not permitted
Received any PAH-approved therapy in last 60 days
Receiving >10 L/min of oxygen supplementation
BCC018: A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma
This study is being done to learn if it is safe to add naxitamab to standard therapy during the Induction phase of care for patients with newly diagnosed high-risk neuroblastoma. Naxitmab is an immunotherapy agent which trains your immune system to target your tumor in a more specific way than chemotherapy does.
This study has 3 phases- screening, treatment, and follow up. If you join the study, during screening we will test a sample of your tumor along with your blood. The tumor sample will be obtained at the same time as you are having surgery or a biopsy. Other testing will be done to make sure you are eligible to receive treatment. If you are eligible for treatment, you will receive five 21 day cycles of anti-cancer medication (induction chemotherapy) along with naxitamab. You will have to stay in the hospital to receive this treatment for at least 6 days of each 21 day cycle. If your screening testing also shows a certain genetic change in your tumor, we may also add a medication that is targeted at that change. If your tumor does not respond adequately to the initial cycles, we may give up to three additional 21 day cycles of chemotherapy with naxitamab. You will also have procedures at certain timepoints during induction that are standard of care for your tumor. These include collecting stem cells for use later in your therapy after Cycle 2. After Cycle 4, you will have surgery to remove as much of the tumor as possible. The treatment phase will last about 8 months, after which you will be in follow up. During your time on the study, we will ask to collect research samples of blood, bone marrow, and tumor. We will be monitoring your progress and health throughout your time on treatment and in follow up.
≤ 21 years of age at initial diagnosis and > 12 months of age at time of enrollment
Receiving any investigational drug
The opioid epidemic among Pennsylvania immigrants: Implications for treatment practices
We plan to interview PA immigrants who have first-hand experience with opioid abuse or who have friends/family/neighbors with opioid abuse experiences. The goal is to highlight areas for improvement, regarding access to treatment and quality of treatment for immigrants. We hypothesize that immigrant status uniquely impacts this group and their rehabilitation journeys, but this has not yet been studied.
There will be one semi-structured, qualitative interview over Zoom, for about 45 minutes. Interviews may be in-person if there is no Zoom access.
$75.00 gift card
PA resident
18 years of age and older
Experience with opioid abuse
Friend or family member with opioid abuse experience
U.S. citizen
Below 18 years of age
No opioid abuse experience
diagnosis of an intellectual/developmental disability
Digital tools for assessment of motor functions and falls in ALS
This is a 48-week, two arm study that incorporates digital tools for assessing motor function in amyotrophic lateral sclerosis (ALS) and healthy controls.During the study, neck- and wrist-worn “activity sensors” (PAMSys, BioSensics, Newton, MA) will be worn by subjects while performing tasks of daily living. Subjects will also complete a motor, speech, and handwriting assessment during site visits. They will complete a digital home assessments of speech, handwriting, and pattern tracing tasks throughout the study, and report any falls which occur on the study tablet. We will explore whether sensor-based functional changes are sensitive to self-reported changes over the length of the study.
During the study, neck- and wrist-worn “activity sensors” (PAMSys, BioSensics, Newton, MA) will be worn by subjects while performing tasks of daily living. Subjects will also complete a motor, speech, and handwriting assessment during site visits. They will complete a digital home assessments of speech, handwriting, and pattern tracing tasks throughout the study, and report any falls which occur on the study tablet.Subjects will be required to visit the study site around the time of 5 consecutive standard ALS clinic appointments.The research study will last approximately 48 weeks.
$240
18 years of age or older
Walking with or without mobility support (such as a cane or walker)
Fluent in written and spoken English
Pregnant or nursing woman
Prisoner or institutionalized individuals
Have any clinically relevant medical history of other disease or diseases that, in the opinion of the research team, exclude the subject from participation (including severe cognitive dysfunction).
Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects
Phase 3, global, randomized, double-blind, placebo-controlled, multi-center study that will evaluate upadacitinib in the treatment of moderate to severe HS in adult and adolescent subjects who have failed to respond to or are intolerant of ant-TNF therapy and/or 1 approved non-anti-TNF-biologic therapy for HS.This study is comprised of a 35-day screening period, a 16 week placebo-controlled, double-blinded treatment period (Period 1), a 20-week re-randomized extension treatment period (Period 2), a 68-week long-term extension treatment period (Period 3) and a 30-day follow-up period.
You will completed 3 study periods over approximately 104 weeks. During that time at different time points you will have your skin examined, ECG, complete questionnaires, and have your labs drawn. In addition you will take the study medication as directed by the research study coordinators.
2 active HS areas
History of previous use ≥ 1 TNF inhibitor for at least 12 weeks and/or 1 approved non-anti-TNF biologic therapy for HS for at least 16 weeks - study coordinator will discuss
Must agree to use daily wash